In a first-of-its-kind move by a large drug maker, Novartis (NVS) raised approximately $2.1 billion last week by selling bonds that are tied directly to its progress in making medicines accessible in certain low- and middle-income countries.

Specifically, the stated goal is to expand the number of patients who receive its brand-name medicines by at least 200% by 2025, as well as programs that market medicines to combat leprosy, malaria, Chagas, and sickle cell disease by at least 50% over the same period. If the company fails to meet those expanded access goals, however, investors will receive higher interest payments.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Novartis deserves points for innovating in a historically boring space (corporate bond market) but not so much on the social impact on this one. Expanding market access in LIMCs is a growth opportunity for every business. Too much emphasis is placed on the product a company happens to sell, when social impact is really about how it operates its business and where it contributes to communities along the entire value chain.

  • May one observe that while I am sure our scribe has faithfully copied the Novartis numbers in the last line, the idea that each recipient of NVS largess got $30,000 / USD “last year” is ________ [fill in the blank].
    NOTE – I did that calculation by eye, and rounded same.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy